Modulating type 1 Interferon may expand treatment options for COVID-19

23336_lores

Source: CDC/ Cynthia S. Goldsmith and A. Tamin

Researchers have, for the first time in nonhuman primates, studied how modulating the signaling of type 1 Interferon (IFN-I), one of the body’s initial defenses against infection, impacts SARS-CoV-2 viral replication and disease progression.

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE